Tracker

THERAPEUTIC DRUG MONITORING IN RHEUMATIC DISEASES

MEASUREMENT OF **BIOLOGICAL DRUG** AND **FREE ANTI-DRUG** ANTIBODIES

EXTEND TREATMENT RESPONSE WHILE **MINIMIZING COSTS** AND **SIDE EFFECTS**

Theradiag
INNOVATION FOR BIOTHERAPIES

Tracker

is your clinical decision-making tool for Rheumatic Diseases

CLINICALLY RELEVANT

- Numerous publications in peer-reviewed journals
- International decision algorithms validated with Tracker kits

COST-EFFECTIVE[1.2]

TDM strategy leads to major cost savings (28 to 50%) related to a biologic treatment

- Rheumatoid arthritis
- Psoriasic
- Juvenile arthritis

ACCURATE

- Accurate quantitative measurement of drugs and anti-drug antibodies
- Detection of free anti-drug antibodies as recommended by international guidelines to fit patient's status
- Performance validated with both Originators and Biosimilars

Therapeutic Drug Monitoring (TDM) strategy leads to major cost savings in Rheumatic Diseases patients while maintaining appropriate efficacy[1.2]



UNIQUE TDM MENU

- Comprehensive menu in inflammatory diseases and oncology
- CE-IVD validation on serum and plasma samples
- Validation in accordance with the 1st WHO international standards (Infliximab and Adalimumab)
- Validation with Princeps and Biosimilars
- Continuous development on new parameters

EASY-TO-USE

- Ready-to-use reagents
- Standardized protocols from sample collection to results interpretation
- ELISA format validated on automated platforms (DS2, DSX, Evolis, etc.)
- CLIA format compatible with i-Track[10], IDS-iSYS and IDS-i10 random access instruments
- Point of Care format for near patient testing
- Validated with IMMUNO-TROL INTERNAL CONTROL

Therapeutic Drug Monitoring (TDM) is a safe method to early measure drug level and detect anti-drug antibodies, guide the therapeutic procedure and optimize treatment efficacy

CLINICALLY VALIDATED

- Routine use tailored to your clinical practice
- Measurement ranges tailored to induction and maintenance treatment phases

Tracker

is a solution validated and supported by pharmaceutical companies to adapt patient treatment

THERAPEUTIC DRUG MONITORING TO IMPROVE CLINICAL OUTCOME AND SUPPORT THE PROPER USE OF DRUGS

NEARLY 30-40%

of patients do not respond to an anti-TNFα treatment[3.4.5]

UP TO 40% OF RHEUMATIC DISEASES PATIENTS

experience relapse in disease activity during maintenance therapy[6]

Pharmacokinetics and pharmacodynamics of biological therapies are highly variable among patients.

Patients with higher dose of drug or slower pharmacokinetics may have drug trough level above the therapeutic window (supratherapeutic).
Higher trough levels may increase side effects.

Patients with lower dose due to the presence of anti-drug antibodies or with low serum albumin concentration or high baseline CRP concentration may have drug trough levels below the therapeutic window (subtherapeutic), leading to reduced drug efficacy.



Therapeutic Drug Monitoring helps physicians **to make rational treatment decisions during the course of Rheumatic Diseases**

Immunogenicity of Biologics[7]	Rheumatoid arthritis	Psoriasic arthritis	Juvenile idiopathic arthritis	Ankylosing Spondylitis
Infliximab	up to 62%	up to 33%	up to 42%	up to 69%
Adalimumab	up to 51%	up to 54%	up to 33%	up to 39%
Certolizumab Pegol	up to 37%	NA	NA	NA
Golimumab	up to 10%	NA	up to 6%	up to 6.47%
Rituximab	up to 21%	NA	NA	NA
Etanercept	up to 13%	NA	up to 6%	NA
Tocilizumab	up to 16%	NA	up to 8%	NA
Secukinumab[8]	NA	< 1%	NA	< 1%



Anti-drug antibodies rates vary widely among biologics regardless of the disease.

Assessment of the immunogenicity of these agents is an important consideration in the treatment decision making process.

WHEN TO PERFORM TDM?



THERAPEUTIC THRESHOLDS

	Rheumatoid arthritis	Axial spondyloarthritis	Psoriasic arthritis
Infliximab[21]	5 - 10 µg/mL	NA	NA
Adalimumab[22]	2 - 8 µg/mL	2,5 - 8 µg/mL	1 - 8 µg/mL
Golimumab[23]	> 4 µg/mL	> 4 µg/mL	> 4 µg/mL
Certolizumab Pegol[22]	20 - 39,9 µg/mL	20 - 39,9 µg/mL	20 - 39,9 µg/mL
Tocilizumab[22]	> 1 µg/mL	NA	NA
Etanercept[24]	> 3,1 µg/mL	NA	NA
Rituximab	NA	NA	NA
Secukinumab	NA	NA	NA

NA, not applicable.

WHEN TO COLLECT BLOOD ON PATIENTS?

- Timing of samples collection is key to interpret the result as the drug concentration varies during the interval between two injections
- Drug and anti-drug measurement is recommended to be performed at Trough Concentration (TC), just before the next dose, both during induction and mainenance:
  - Target ranges are defined using TC
  - Free anti-drug antibodies are mostly detectable at TC



INTERPRET DOSING INFORMATION

- Drug levels required to improve clinical outcomes may vary between patients and depend on the desired therapeutic endpoint
- In patients with undetectable drug levels, anti-drug antibody (ADAb) quantification helps to identify how to improve patient response
- In patients with high anti-drug antibodies levels, a switch in-class may be necessary
- In patients with low anti-drug antibodies levels, the addition of an immunosuppressive drug may improve clinical outcomes
- If your patients are good responders with higher drug trough levels, dose decrease may be possible without affecting clinical outcomes

Example of therapeutic decision algorithm in patient with loss of response

	Negative Anti-drug Antibodies	Positive Anti-drug Antibodies
Therapeutic level of Drug	Switch out of therapeutic class	Retest
Subtherapeutic level of Drug	Treatment Optimization	Switch in-class



IS = immunosuppressant

* These findings do not constitute a diagnosis in any case. They reflect information available in published peer-reviewed literature and guidelines and should be independently evaluated by the treating clinician and used to complete other clinical and biological information in accordance with clinician's independent medical judgment.

A **COMPLETE SOLUTION** ADAPTED TO YOUR MONITORING NEEDS

ez-Tracker: Rapid **Immunofluorescence** Test

- Samples: whole blood, serum, plasma
- Result in 10 to 12 minutes depending on the parameter
- Excellent performance thanks to Time Resolved Fluorescence technology

LISA TRACKER: Automatable **ELISA** range

- Samples: serum, plasma
- Duo sets (drug and anti-drug)
- Ready-to-use reagents and standardized protocols
- Flexible test formats to adapt to the volume of activity

i-Tracker: **Random Access** CLIA solution

- Continuous loading of samples and reagents
- Samples: serum, plasma
- Result < 40 min
- System managed test protocol
- Ready-to-use reagents with system-managed sample dilutions
- High throughput analysis: 60 tests/hour
- STAT function
- Connectable to sample conveyors

Assay of drugs and of free and total anti-drug antibodies

Calibration on NIBSC / WHO international standards

Validated on originator and biosimilars

Validated through more than 100 clinical studies

REFERENCES

1. Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017 Jan;52(1):19-25.
2. Gómez-Arango C, Gorostiza I, Úcar E, García-Vivar ML, Pérez CE, De Dios JR, Alvarez B, Ruibal-Escribano A, Stoye C, Vasques M, Belzunegui J, Escobar A, Trancho Z, Ruiz Del Agua A, Del Río L, Jorquera C, Diez E, Martínez A, Nagore D. Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial. Rheumatol Ther. 2021 Sep;8(3):1323-1339.
3. So Alexander. Rhumatologie La patiente polyarthritique qui ne répond pas à l'anti-TNF. Rev Med Suisse 2007 ; 3 : 60-2.
4. Yoosuf N, Maciejewski M, Ziemek D, Jelinsky SA, Folkersen L, Müller M, Sahlström P, Vivar N, Catrina A, Berg L, Klareskog L, Padyukov L, Brynedal B. Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. Rheumatology (Oxford). 2022 Apr 11;61(4):1680-1689.
5. Bek S, Bojesen AB, Nielsen JV, Sode J, Bank S, Vogel U, Andersen V. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):403-411.
6. Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-Puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmun Rev. 2020 May;19(5):102509.
7. Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021 Feb;17(2):81-97. doi: 10.1038/s41584-020-00540-8. Epub 2020 Dec 14. PMID: 33318665.
8. Atul Deodhar et al., Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. The Journal of Rheumatology April 2020, 47 (4) 539-547; DOI: https://doi.org/10.3899/jrheum.190116.
9. Papamichael K et al. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3.
10. Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR.Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. J Crohns Colitis. 2018 May 25;12(6):653-661. doi: 10.1093/ecco-jcc/jjy003.
11. Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017 Sep;23(9):1510-1515.
12. Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014 Aug;109(8):1250-6. doi: 10.1038/ajg.2014.146.
13. Roblin X, Vérot C, Paul S, Duru G, Williet N, Boschetti G, Del Tedesco E, Peyrin-Biroulet L, Marc Phelip J, Nancey S, Flourie B. Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF? Inflamm Bowel Dis. 2018 Apr 26.
14. Papamichael K, Vajravelu RK, Osterman MT, Cheifetz AS. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018 Mar;63(3):761-767. doi: 10.1007/s10620-018-4917-7.
15. 3rd European Evidence-based Consensus on the Diagnosis and Management of Ulcerative Colitis-J Crohns Colitis. 2017; 11(6):649-670. 17.
16. Afif W et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9.
17. Roblin X et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases Am J Gastroenterol. 2014 Aug;109(8):1250-6.
18. L'Ami M.J et al. - Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomized clinical trial-Ann Rheum Dis 2018 Apr;77(4):484-487.
19. Amiot A et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8.
20. Paul S et al. Infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Oct;42(7):939-40.
21. Irving P et al. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Gastroenterology 2022; 162:1512–1524.
22. Krieckaert C, Hernández-Breijo B, Gehin JE, le Mélédo G, Balsa A, Jani M, Mulleman D, Navarro-Compan V, Wolbink G, Isaac J, van Tubergen A. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. 2022 Jun;8(2):e002216.
23. Gehin JE, Warren DJ, Syversen SW, Lie E, Sexton J, Loli L, Wierød A, Bjøro T, Kvien TK, Bolstad N, Goll GL. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. Scand J Rheumatol. 2021 Nov;50(6):445-454.
24. Daïen CI, Daïen V, Parussini E, Dupuy AM, Combe B, Morel J. Etanercept Concentration in Patients with Rheumatoid Arthritis and Its Potential Influence on Treatment Decisions: A Pilot Study. J Rheumatol. 2012 Aug;39(9):1533-1538.

ORDERING INFORMATION

i-Tracker

Reference	Designation	Packaging
CTx 002-50/100	i-Tracker Drug	50 / 100 tests
CTx 003-50/100	i-Tracker Anti-Drug	50 / 100 tests

x = Infliximab 100 tests / Adalimumab 100 tests / Vedolizumab 50 tests / Ustekinumab 50 tests / Golimumab 50 tests / Rituximab 50 tests / Certolizumab Pegol 50 tests (Etanercept 50 tests, Tocilizumab 50 tests, Risankizumab 50 tests, Natalizumab 50 tests and Ocrelizumab 50 tests: in development)

LISA TRACKER

Reference	Designation	Packaging
LTx 005	LISA TRACKER Duo Drug + ADAb	2 x 48 tests
LTx 002-48	LISA TRACKER Drug	48 tests
LTx 003-48	LISA TRACKER Anti-Drug	48 tests
LTT 004-96	LISA TRACKER TNF	96 tests

x = Infliximab / Adalimumab / Etanercept / Certolizumab Pegol / Golimumab / Rituximab / Secukinumab / Tocilizumab / Bevacizumab / TRastuzumab / Ustekinumab / Vedolizumab

ez-Tracker

Reference	Designation	Packaging
ETx 002-24	ez-Tracker Drug	24 tests
ETx 003-24	ez-Tracker Anti-Drug Antibodies	24 tests
ETI 003T-24	ez-Tracker Infliximab Total Ab	24 tests

x = Infliximab / Adalimumab / Golimumab / Vedolizumab / Ustekinumab (Etanercept : in development)

All Tracker products are validated on princeps molecules and associated biosimilars (when available).

IMMUNO-TROL Internal Quality Control

A range of ready-to-use, internal Quality Control sera, CE marked, dedicated to the pharmacological dosage of biotherapies

For i-Tracker

Reference	Designation	Packaging
CTx 002-PC	Immuno-Trol Drug: Positive control two levels	2 x 500 µl
CTx 003-PC	Immuno-Trol anti-Drug: Positive control two levels	2 x 1,5 ml

x = Infliximab / Adalimumab / Vedolizumab / Ustekinumab / Golimumab / Rituximab / Certolizumab Pegol (Etanercept, Tocilizumab, Risankizumab, Natalizumab and Ocrelizumab: in development)

For LISA TRACKER

Reference	Designation	Packaging
LTx 002-PC	Immuno-Trol Drug: Positive control two levels	2 x 250 µl
LTx 003-PC	Immuno-Trol anti-Drug: Positive control two levels	2 x 1 ml

x = Infliximab / Adalimumab / Etanercept / Certolizumab Pegol / Golimumab / Rituximab / Secukinumab / Tocilizumab / Bevacizumab / TRastuzumab / Ustekinumab / Vedolizumab

For ez-Tracker

Reference	Designation	Packaging
ETx 002-C / ETx 003-C	ez-Tracker Drug / ADAs Controls	2 x 1 mL
ETx 002-CAL / ETx 003-CAL	ez-Tracker Drug / ADAs Calibrators	2 x 1 mL

x = Infliximab / Adalimumab / Golimumab / Vedolizumab / Ustekinumab (Etanercept : in development)

Theradiag (France) - Boditech (South Korea)

CE

Theradiag
INNOVATION FOR BIOTHERAPIES

14 rue Ambroise Croizat
77183 Croissy Beaubourg
France

Phone : +33 (0) 1 64 62 10 12
Fax : +33 (0) 1 64 62 09 66
info@theradiag.com
www.theradiag.com

Read carrefully the instruction for use of the product insert before use. Pictures may differ from actual products.

Tracker 8p Rh - V.10/2023 - EN